Work

The prognostic value of histological grade determined after neoadjuvant chemotherapy of breast cancer

Year: 2024

Type: article

Abstract: Histological grade is a validated prognostic factor of breast cancer but may show alterations following neoadjuvant chemotherapy (NACT). Its reporting after NACT is recommended by several guidelines, but evidence of its retained prognostic impact is scarce. Patients treated with NACT followed by surgery and having sufficient residual tumour for the determination of grade were analysed for the survival effects of posttreatment grade (yG). Kaplan-Meier analyses and the log-rank test were applied, followed by the univariable and multivariable Cox proportional hazards models. The cohort comprised 355 patients with known yG, and 320 of them had also a pretreatment grade available. Pretreatment grade changed in 99/320 (31 %) cases following NACT, and downgrading was more common (n=78/320, 24 %) than upgrading (21/320, 7 %). Among 355 breast cancer patients, those with yG3 (poorly differentiated) tumours (n=155) had worse 5-year relapse-free and overall survival estimates than those with yG2 (n=169) or yG1 (n=31) tumours. This was also substantiated by univariable analysis; however, yG lost its significance in the multivariable model. Post-NACT histological grade has a prognostic impact, but does not seem to be an independent prognosticator in the post-NACT setting; however, these results lend support for its reporting by pathologists after primary systemic treatment. • Pretreatment grade changes after primary chemotherapy in about a third of patients. • This change is more commonly a downgrading. • Posttreatment grade is prognostic based on Kaplan-Meier and univariable analyses. • Posttreatment grade loses significance in multivariable analysis. • The recommendation of determining posttreatment grade can be substantiated.

Source: Pathology - Research and Practice

DOI: 10.1016/j.prp.2024.155732